Market Overview of Wuhan Hiteck Biological Pharmaceutical (300683.SZ)
On the trading day that concluded at 08:22 AM Central Europe time, the shares of Wuhan Hiteck Biological Pharma (ticker 300683.SZ) closed flat, reflecting a 0 % change over the 24‑hour period. The current market price is approximately CNY 23.94 on the principal exchanges that list the stock.
The company’s share supply stands at 132.8 million, while its market capitalisation amounts to CNY 3.1 billion. In the past 24 hours, roughly CNY 159.1 million worth of the stock was traded, indicating a moderate level of liquidity. Compared with the close of the previous month’s end, the shares have declined by 10.1 %, signalling a contraction in investor sentiment.
A technical assessment shows that the simple moving average over the last 200 days sits at CNY 26.17. In the broader weekly context, the 52‑week high was CNY 50.68 on 2 April 2026, while the 52‑week low reached CNY 22.37 on 14 September 2026, placing the current price nearer the lower bound of that range.
Peer Performance Snapshot (Last 24 Hours)
| Company | Ticker | 24‑hour Change | Current Price | Market Capitalisation | P/E Ratio* |
|---|---|---|---|---|---|
| Saimo | 300466.SZ | 0 % | CNY 8.73 | CNY 3.7 bn | – |
| Shandong Wohua Pharmaceuti | 002107.SZ | 0 % | CNY 6.39 | CNY 3.7 bn | 28.64 |
| Shinry | 300745.SZ | 0 % | CNY 22.12 | CNY 3.7 bn | – |
| Shenyu Communication Techn | 300563.SZ | 0 % | CNY 21.68 | CNY 3.7 bn | 62.09 |
| Shiyue Daotian Lt‑h | 9676.HK | +0.36 % | HKD 4.15 | HKD 4.4 bn | 8.01 |
*Price‑to‑earnings ratios are provided where available and can serve as a quick gauge of valuation relative to earnings.
Company Profile
Wuhan Hiteck Biological Pharma Co., Ltd. operates within China’s health‑care sector, focusing on the research, development, production, and sale of biopharmaceutical products. The firm’s flagship offerings include freeze‑dried powder injections of rat nerve growth factor, anti‑hepatitis B transfer factor, thrombin, and related chemical agents. All products are manufactured and distributed primarily within the domestic market.
The company’s official website, accessible at www.hiteck.com.cn , provides detailed information on its product portfolio, R&D pipeline, and corporate governance. Wuhan Hiteck Biological Pharma is listed on the Shenzhen Stock Exchange, where it is traded under the ticker 300683.SZ.
Market Context and Outlook
The flat performance of Wuhan Hiteck Biological Pharma during the most recent trading window mirrors the broader trend among its peer group, many of which also recorded negligible price movements. This collective stasis may reflect a market‑wide pause as investors digest sector‑specific data, macro‑economic signals, and corporate earnings forecasts.
Given the current price’s proximity to the 52‑week low, there is a potential upside should the company release positive development updates—such as new regulatory approvals, expanded production capacity, or successful clinical trial milestones. Conversely, the sustained downward drift since the previous month suggests that any negative news or broader market sell‑off could exacerbate the decline.
Investors should monitor the company’s earnings reports, product launch timelines, and any announcements related to regulatory approvals. Additionally, comparative valuation metrics, such as the price‑to‑earnings ratio, can help assess whether the stock is undervalued relative to peers that exhibit stronger earnings performance.
*This article provides an overview based on publicly available trading data and market metrics. Readers are encouraged to conduct further research or consult a financial professional before making investment decisions.
